Does Regence Cover Propecia? Formulary Details, Costs, and Alternatives

The direct answer, and its limits

Propecia (finasteride 1 mg, oral tablet) is FDA-approved only for androgenetic alopecia in men. Regence, like most U.S. commercial insurers, classifies drugs used solely for that indication as cosmetic and excludes them from standard pharmacy benefits on the majority of its commercial, individual marketplace, and small-group plans. This exclusion applies to brand-name Propecia and to generic finasteride 1 mg when the prescription is written for hair loss. It does not automatically apply to finasteride 5 mg (Proscar) when prescribed and coded for BPH, which is commonly covered as a low-tier generic.

That said, insurer formularies change, self-funded employer plans can opt out of standard exclusions, and Regence operates as separate corporate entities in Oregon, Washington, Idaho, and Utah, each of which files its own plan documents. A general statement about "Regence" cannot substitute for checking your specific plan's Summary of Benefits and Coverage (SBC) and formulary lookup tool. Treat any coverage detail here as a starting point for verification, not a final answer for your plan as of any particular date.

Finasteride 1 mg versus 5 mg: why the dose matters for coverage

Finasteride is manufactured at two FDA-approved strengths with two different approved uses. The 5 mg tablet is approved for symptomatic BPH and is typically stocked as a Tier 1 generic, with a diagnosis code for BPH expected on the claim. The 1 mg tablet is approved specifically for male pattern hair loss and is the strength insurers most often exclude.

Some patients have used quartered 5 mg tablets to approximate a 1 mg hair-loss dose. This is pharmacologically plausible, since a quarter of a 5 mg tablet yields roughly 1.25 mg, but it raises two separate problems. First, billing a BPH-indicated drug for an unapproved indication without a supporting diagnosis can prompt a claims audit or retroactive denial. Second, pill-splitting introduces dosing variability that a clinician should weigh against simply paying cash for the correctly dosed 1 mg generic, which is often inexpensive enough that the workaround is not worth the risk. This is a judgment a prescriber should make with the patient, not a substitute for individualized dosing advice.

What finasteride costs without insurance coverage

Brand-name Propecia is priced well above its generic equivalents at most retail pharmacies. Generic finasteride 1 mg is broadly available at low monthly cash prices through pharmacy discount programs and retailer generic drug lists, often landing below what a typical Tier 1 or Tier 2 copay would be on a plan that does cover it. Because cash prices for generics move with pharmacy, discount-card network, and region, and because this article cannot verify current pricing at any specific pharmacy, confirm the price at the pharmacy or discount platform you plan to use before assuming a number quoted anywhere online, including here, is current.

Compounded topical finasteride through a 503A compounding pharmacy is a separate category: it is not an FDA-approved product, it is prepared under a prescription for an individual patient, and its cost, availability, and quality-control profile differ from commercially manufactured oral finasteride. Patients considering it should understand that compounded products do not go through the same FDA review as the approved tablet.

What the evidence actually shows about efficacy

Oral finasteride 1 mg lowers scalp and serum dihydrotestosterone (DHT) by inhibiting type II 5-alpha reductase, and DHT-driven follicle miniaturization is the accepted mechanism behind androgenetic alopecia. The pivotal trials that supported FDA approval in 1997 enrolled young and middle-aged men with mild to moderate vertex hair loss and followed them for one to two years, comparing hair count and clinician/patient-rated appearance against placebo. The finasteride group showed a clear separation from placebo, with most treated men maintaining or gaining hair count and most placebo-treated men continuing to lose hair over the same period. Exact percentages and hair-count figures are widely cited in secondary sources, but a precise number should be checked against the original registration trial publications rather than repeated as a fixed fact, since this draft cannot independently verify a specific citation for those figures at this time.

Longer-term follow-up data, generally covering up to five years, describe continued benefit relative to placebo, with most of the gain occurring in the first one to two years and effect maintenance afterward for men who continue treatment. Discontinuation reverses the DHT suppression and, over months, the hair-count benefit.

Finasteride is contraindicated in pregnancy because of a boxed warning describing risk to male fetal external genitalia from exposure, including through handling of crushed or broken tablets; women who are or may become pregnant should not handle crushed finasteride tablets.

Side effects and the post-finasteride discussion

The FDA-approved label for finasteride identifies sexual side effects, including decreased libido, erectile dysfunction, and ejaculation disorders, occurring in a small percentage of users above the placebo rate in clinical trials. The label has also been updated to note post-marketing reports of these symptoms persisting after discontinuation in some men, along with reports of male infertility and semen-quality changes.

Whether a distinct, persistent "post-finasteride syndrome" exists as a separate clinical entity, independent of pre-existing risk factors and reporting bias, remains actively debated in the dermatology and urology literature, and existing reviews describe the evidence as limited by a lack of prospective, controlled data. Prospective randomized research designed to characterize this question directly is understood to be underway; specific trial identifiers should be confirmed against a current clinicaltrials.gov search rather than assumed from a secondary summary. Anyone considering finasteride, especially with a personal history of depression, anxiety, or sexual dysfunction, should discuss this uncertainty explicitly with a prescriber before starting, and should know that stopping the drug is always an option if concerning symptoms develop.

Bottom line for this section, stated plainly: finasteride 1 mg is FDA-approved for male androgenetic alopecia, works by lowering DHT, and shows benefit over placebo in the trials that supported its approval and in longer follow-up; a small percentage of users report sexual side effects, some of which are reported to persist after stopping in a subset of cases, and the degree to which that represents a distinct persistent syndrome versus other explanations is not settled in the literature as of this writing.

Should you appeal a Regence denial?

A cosmetic-category exclusion is different from a medical-necessity denial, and that difference matters for whether an appeal is worth the effort. A standard prior-authorization appeal argues that a specific patient meets clinical criteria within a covered benefit. When the entire drug class is excluded from the benefit design, there is no clinical criterion to argue toward, because the plan does not cover the category regardless of the clinical picture.

Two situations are worth checking rather than assuming the exclusion is final. First, if hair loss is tied to a diagnosed mental health condition such as major depressive disorder or body dysmorphic disorder, a prescriber can write a letter of medical necessity framing treatment around the psychiatric diagnosis rather than the cosmetic one; whether this succeeds depends on plan language and is not guaranteed. Second, large-employer self-funded plans administered by Regence can set their own formulary rules independent of Regence's standard commercial formulary, so a plan-specific SBC and formulary lookup, or a call to the number on the back of the member ID card, is more reliable than a general statement about "Regence policy."

Alternatives that do not depend on insurance coverage

Generic oral finasteride paid out of pocket remains the most studied and lowest-cost prescription option for men who qualify clinically. Topical minoxidil is available over the counter without a prescription and works through a different mechanism, so the two are sometimes combined; combination use should still be discussed with a clinician rather than self-directed, particularly regarding expectations and side effects. Oral low-dose minoxidil for hair loss is an off-label use of a blood pressure medication and carries its own cardiovascular considerations that a prescriber needs to review.

Low-level laser therapy devices with FDA 510(k) clearance for androgenetic alopecia are available without a prescription and represent a device-based, non-drug option, though device clearance is a lower evidentiary bar than a full drug approval and effect sizes vary across studies. Platelet-rich plasma (PRP) injections are a procedural option offered by some dermatology practices; PRP protocols and outcomes vary by clinic, evidence quality across trials is mixed, and PRP is not typically covered by Regence or most other insurers because it is considered a cosmetic procedure.

How Regence's structure affects your specific answer

Regence is part of the Cambia Health Solutions family and operates as separate licensed entities in Oregon, Washington, Idaho, and Utah. Each entity files its own plan documents with its state insurance regulator, and formulary details, including whether an exclusion applies, can differ between a fully insured individual plan, a fully insured group plan, and a self-funded employer plan administered by Regence as a third-party administrator. State mental health parity laws exist in several states, including Oregon and Washington, but whether such a law strengthens a specific appeal depends on how the claim is framed and coded, not on the existence of the law alone; this is a question for the prescriber's billing staff or a benefits specialist, not a general rule that applies uniformly.

What to discuss with a prescriber before starting finasteride

A clinician evaluating hair loss should confirm the pattern is consistent with androgenetic alopecia rather than another cause of hair thinning, review your medication list, and discuss the sexual side-effect profile and the unresolved post-discontinuation symptom question directly rather than in passing. Because finasteride lowers PSA levels, a baseline PSA before starting is a reasonable discussion point for men old enough for prostate cancer screening, since a lowered PSA can complicate later screening interpretation; how to interpret a PSA value in a man taking finasteride is a clinical decision for the prescriber, not something to calculate independently. Visible results, when they occur, typically take several months to appear and continue to build over a year or more; stopping the drug leads to gradual loss of the gained benefit as DHT levels return to baseline.

Verification checklist: what is stable versus what you must check today

Use this to separate facts that do not change plan-to-plan or month-to-month from facts that are specific to your Regence plan, your state, and today's pricing.

Stable, federal or clinical facts (do not need re-verification per plan):

• Finasteride 1 mg (Propecia) is FDA-approved for male androgenetic alopecia; finasteride 5 mg (Proscar) is FDA-approved for BPH. These are two different approved uses of the same molecule at different doses.
• Finasteride carries a boxed pregnancy warning regarding risk to a male fetus from exposure.
• Finasteride lowers PSA, which is a recognized confounder for prostate cancer screening in men taking it.
• The mechanism of action (5-alpha reductase inhibition, reduced DHT) is established pharmacology, not plan-dependent.

Date-sensitive, plan- or market-specific facts (verify before relying on them):

• Whether your specific Regence plan (Oregon, Washington, Idaho, Utah; individual, group, or self-funded employer) currently excludes finasteride 1 mg. Check the current SBC and the online formulary tool, not a general statement about "Regence."
• Whether your plan requires a documented BPH diagnosis code to pay for finasteride 5 mg.
• Current cash price for generic finasteride 1 mg at the specific pharmacy or discount program you intend to use.
• Current retail price for brand Propecia, which can vary by pharmacy and changes over time.
• Whether your employer's self-funded plan has opted out of the standard cosmetic exclusion.
• Whether an appeal pathway tied to a documented psychiatric diagnosis is accepted by your plan; this varies by insurer and by how the claim is coded.

How to verify, in order:

1. Log in to the Regence member portal and search the formulary by drug name for your specific plan.
2. Read the SBC's exclusions section for "cosmetic" or "hair loss" language.
3. Call the pharmacy benefits number on the back of the member ID card and ask specifically about finasteride 1 mg for androgenetic alopecia versus finasteride 5 mg for BPH.
4. If self-employed or covered through a large employer, ask HR or benefits administration whether the plan is self-funded and whether it uses Regence's standard exclusions.

When to seek care rather than self-manage

Sudden or patchy hair loss, hair loss with scalp pain, redness, or scarring, or hair loss accompanied by other new symptoms is not typical androgenetic alopecia and warrants an in-person evaluation rather than starting an over-the-counter or telehealth prescription based on assumed diagnosis. Anyone who develops mood changes, new depression, or significant sexual side effects while taking finasteride should contact their prescriber promptly rather than waiting for a routine follow-up.

Evidence boundary: It is established that finasteride 1 mg is FDA-approved for androgenetic alopecia and lowers DHT through 5-alpha reductase inhibition, and that most commercial insurers, including Regence on most of its plans, treat hair-loss drugs as a cosmetic exclusion. It is plausible but not fully settled that a distinct persistent symptom syndrome exists after finasteride discontinuation, separate from other explanations, given the current state of prospective controlled research. It is not established, and cannot be confirmed from general sources, exactly which Regence plan in which state currently covers or excludes any specific finasteride prescription, or what any pharmacy is charging today; those facts require direct verification against your plan documents and current pharmacy pricing.

A note on this draft: several claims in an earlier version of this article relied on specific citations, quotations, and numeric figures that could not be independently verified against primary sources during this revision, including attributed quotations and precise trial statistics. Those items have been removed, generalized, or flagged above for confirmation by clinical review before publication. Insurer coverage details and cash prices are date-sensitive and should be re-verified at the time a reader acts on this article.